FEBRUARY 14, 2020
Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020
FEBRUARY 4, 2020
Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference

Outlook Therapeutics…

…is a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).


ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (or mAb) that inhibits VEGF and associated angiogenic activity.

ONS-5010 is currently being evaluated in our Phase 3 program for wet AMD and is expected to be filed with the FDA as a new BLA for this ophthalmic indication. Outlook Therapeutics also intends to commence additional clinical trials for ONS-5010 in DME and BRVO in 2020.

If approved, ONS-5010 will be the first and only FDA-approved ophthalmic formulation of bevacizumab to treat retinal diseases.